Compare CIK & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIK | GANX |
|---|---|---|
| Founded | 1987 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.2M | 159.2M |
| IPO Year | N/A | 2021 |
| Metric | CIK | GANX |
|---|---|---|
| Price | $2.81 | $1.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 115.4K | ★ 1.0M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 9.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.50 | $1.41 |
| 52 Week High | $3.19 | $4.34 |
| Indicator | CIK | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 42.19 | 34.89 |
| Support Level | $2.79 | $1.72 |
| Resistance Level | $2.84 | $2.07 |
| Average True Range (ATR) | 0.02 | 0.17 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 29.41 | 10.77 |
Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. Credit Suisse serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.